Ligand Pharmaceuticals Incorporated announced that it has entered into a worldwide license agreement with Emergent BioSolutions Inc. Under the license, Emergent will use the OmniRat, OmniMouse and OmniFlic technologies to discover fully human mono- and bispecific antibodies. Ligand will be eligible to receive annual access payments, fees on patent filings, potential milestone payments and royalties on future net sales of any antibodies discovered under the license.